Marburg I mutant of factor VII activating protease (FSAP) as risk factor for arterial thrombosis and methods of detecting FSAP and FSAP mutations
An arterial thrombosis risk factor comprising one or more of the identified mutants of coagulation factor VII activating protease (FSAP) is described. In addition, diagnostic determination methods for detecting these mutants which are identified as risk factors are described.
1. A method of detecting atherothrombosis risk in an individual, comprising:
obtaining one or more body fluids from said individual;
determining Factor VII Activating Protease (FSAP) protein concentration in said one or more body fluids of the individual; and
determining whether there is a reduced FSAP protein concentration in one or more of the body fluids compared to the FSAP protein concentration in a standard sample;
wherein, atherothrombosis risk in the individual is indicated by an FSAP protein concentration that is reduced compared to the FSAP protein concentration in the standard sample.
2. The method of claim 1 , wherein the FSAP protein concentration is determined by incubating said one or more body fluids of the individual with an FSAP-specific antibody or a fragment thereof.
3. The method of claim 1 , wherein said one or more body fluids are chosen from one or more of whole blood, blood plasma, serum, lymphatic fluid, cerebrospinal fluid, pleural fluid, pericardial fluid, peritoneal fluid, synovial fluid, tears, seminal plasma, and cell lysates.
4. The method of claim 3 , wherein said one or more body fluids comprise blood plasma.
5. The method of claim 1 , wherein the FSAP protein concentration is reduced by 50% or more compared to the FSAP protein concentration in the standard sample.
6. The method of claim 1 , further comprising determining the ability of the FSAP of the individual to activate one or more single-chain plasminogen activators.
7. The method of claim 6 , further comprising comparing the ability of the FSAP of the individual to activate single chain plasminogen activators against that of FSAP from a standard.
8. The method of claim 6 , wherein the ability of the FSAP of the individual to activate single chain plasminogen activators is measured by:
(a) incubating said one or more body fluids of the individual on a solid support to immobilize FSAP on said solid support;
(b) washing the support; and
(c) incubating the FSAP immobilized on the support with reagents which allow determination of the ability of the FSAP immobilized on the support to activate one or more single-chain plasminogen activators.
9. The method of claim 8 , wherein said reagents which allow determination of the ability of the FSAP immobilized on the support to activate one or more single chain plasminogen activators comprise a single-chain plasminogen activator substrate.
10. The method of claim 1 , further comprising determining the Factor VII activating activity of the FSAP from the individual.
11. The method of claim 6 , comprising determining the prourokinase activating activity of the FSAP from the individual.
12. The method of claim 11 , further comprising comparing the prourokinase activating activity of the FSAP from the individual against the prourokinase activating activity of FSAP from a standard.
13. The method of claim 11 , wherein the prourokinase activating activity of the FSAP from the individual is measured by:
(a) incubating said one or more body fluids of the individual on a solid support to immobilize FSAP on said solid support;
(b) washing the support; and
(c) incubating the FSAP immobilized on the support with reagents which allow determination of the prourokinase activating activity of the FSAP immobilized on the support.
14. The method of claim 13 , wherein said reagents which allow determination of the prourokinase activating activity of the FSAP immobilized on the support comprise a prourokinase substrate.
15. The method of claim 6 , comprising determining the single-chain tissue plasminogen activator (sc-tPA) activating activity of the FSAP from the individual.
16. The method of claim 15 , further comprising comparing the sc-tPA activating activity of the FSAP from the individual against the sc-tPA activating activity of FSAP from a standard.
17. The method of claim 15 , wherein the sc-tPA activating activity of the FSAP from the individual is measured by:
(a) incubating said one or more body fluids of the individual on a solid support to immobilize FSAP on said solid support;
(b) washing the support; and
(c) incubating the FSAP immobilized on the support with reagents which allow determination of the sc-tPA activating activity of the FSAP immobilized on the support.
18. The method of claim 17 , wherein said reagents which allow determination of the sc-tPA activating activity of the FSAP immobilized on the support comprise a sc-tPA substrate.
19. The method of claim 1 , further comprising analyzing at least one of the genomic DNA, mRNA, or cDNA of the individual to determine whether the individual has a heterozygous or homozygous mutation in the FSAP nucleotide sequence, said mutation comprising a G to A base exchange at nucleotide position 1601, said nucleotide sequence position defined according to the proenzyme nucleotide sequence of SEQ ID NO:1.
20. The method of claim 1 , further comprising analyzing at least one of the genomic DNA, mRNA, or cDNA of the individual to determine whether the individual has a heterozygous or homozygous mutation in the FSAP nucleotide sequence, said mutation comprising a G to C base exchange at nucleotide position 1177, said nucleotide sequence position defined according to the proenzyme nucleotide sequence of SEQ ID NO:1.